Organisation paid for research Program year 2025 Source: CMS Open Payments

Preferred Primary Care Physicians

Neither a doctor nor a teaching hospital

Research payments

$3,436,917

1,472 payments

Through program year 2025, Preferred Primary Care Physicians is reported as receiving $3,436,917 in research payments, across 1,472 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$139,489	47
2024	Research	$497,712	68
2023	Research	$670,686	200
2022	Research	$862,545	530
2021	Research	$677,646	197
2020	Research	$339,847	293
2019	Research	$248,991	137

Breakdown

Who paid Research payments · program years 2019–2025

GlaxoSmithKline, LLC. $1,009,047 298 payments
Merck Sharp & Dohme Corporation $882,065 57 payments
Novo Nordisk AS $750,276 967 payments
Novartis Pharmaceuticals Corporation $342,843 21 payments
Moderna TX, Inc. $219,965 5 payments
Amgen Inc. $85,223 9 payments
Pfizer Inc. $51,990 46 payments
AstraZeneca Pharmaceuticals LP $37,999 8 payments
AbbVie, Inc. $19,412 15 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $15,023 5 payments

Studies the money was for Research payments · program years 2019–2025

V503-049 A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age $796,058 31 payments
A Phase 3, Randomized, Placebo-Controlled, Observer-Blind, Multi-Count $525,416 160 payments
Study name not reported $303,702 67 payments
Ex9924-4473 $280,648 618 payments
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $219,965 5 payments
Ex9536-4388 $191,913 179 payments
Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $173,959 13 payments
An Open Label Study to Assess Response to Influenza Vaccine in Ofatumumab Treated Patients. $137,763 3 payments
Nn9924-4558 $105,044 40 payments
Nn9535-4416 $76,370 32 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.